Carcinoma of unknown primary: retrospective study about 437 patients treated at salah azaiez Institute

##plugins.themes.academic_pro.article.sidebar##

Published Apr 11, 2013
Download
pdf
Vol. 91 No. 3 (2013): Issue Mar 2013

##plugins.themes.academic_pro.article.main##

Rania Fehri
Hela Rifi
Adel Alboueiri
Dhafer Malouche
Mouna Ayadi
Henda Rais
Amel Mezlini

Abstract

Background: Carcinoma of unknown primary (CUP) origin is defined as histologically confirmed metastatic carcinoma in the absence of a detectable primary site at the time of making therapeutic decision.
aim: To report epidemiological, clinical, histopathological, therapeutic, and prognostic features of CUP’s patients collected at the Salah Azaiez institute (SAI).
methods:We reviewed retrospectively the files of 437 CUP-patients in SAI between January 1994 and December 2006. We analyzed their epidemiological, clinical, histological and therapeutic features and classify patients in favourable and unfavourable subsets. Statistical analysis was performed with R software. Survival curves were made with the method of Kaplan-Meier.
results: We collected 437 patients with a median age of 60 years and a sex-ratio of 1.8. CUP are metastatic to lymph nodes (56.5%), bones (29.7%) and liver (28%). 33% of patients had a unique site of metastases. Adenocarcinoma represented 50.5% of cases while 10.5% are classified in the favourable subgroup. 141 out 437 patients received palliative chemotherapy, 83% of them by cisplatin-based regimens obtaining 13% (58 patients) of objective response. Median survival was 7 months. 24 out 58 patients (41%) relapsed. Poor prognostic factors for survival were: multiple metastases (p=0.00033), >3 sites (p=0.03), undifferentiated carcinoma and adenocarcinoma (p>0.0001), liver metastases (p=0.0137), bone (p=0.00653) and adrenal gland (p=0.0334) metastatic sites. Patients who underwent chemotherapy (p>0.001) and who received cisplatbased regimen had better survival (p=0.01).
Conclusion: Our retrospective study done in the context of a minimal and biological work-up confirmed the difficulty to find the primary in CUP.

Keywords:

Metastases, carcinoma, unknown primary, survival, prognosis

##plugins.themes.academic_pro.article.details##

References

  1. Pouessel D , The zenas S, C uline S, Becht C, Senesse P, Ych ou M. He patic metas ta se s from carcinomas of unknown prim ary sit e. Experienc e o f the Montpellier C ancer Center. G astr o e ntero l C lin Biol 2005; 29: 1224-32.
  2. Pav lidis N, Fi zaz i K. Carcin oma of unk nown primary (CUP). Crit Rev On col Hematol 2009; 69: 271-8.
  3. Abbruz zese JL, Abbruzzese MC, Hess KR, Raber MN , Lenzi R, F r ost P. Unkn own primary carc inoma: n atura l h istory and prognostic facto rs in 657 consecutiv e patients. J Clin On col 1994; 12: 1272- 80.
  4. Altman E, Cad ma n E. An analys is o f 1539 p at ie nts with cancer of unkn ow n prim ary site. Ca ncer 1986; 57: 120-4.
  5. Laz aridis G, Pentheroudakis G, Fountzilas G, Pav lidis N. L iver m eta st ase s f r om ca nce r of un know n p r im a ry (CUP L): A re trospective a nalysis of present at ion, m anagement and progno sis in 4 9 patients and sys te matic review of the literatu re. C ancer Tr eat Rev 2008 ; 34 : 693 - 700.
  6. Be n A bdallah M , Zeha ni S, Ben Ayoub W. North Tunisia Cancers R egister: data for 1 999-2003. 2nd edition Tun is. 2009.
  7. Van De Wouw AJ, Jan ssen- Heijne n ML, Coebergh JW, Hillen HF. Epide mio logy of unkn own pri mar y tumours; in ci de nc e and po pul a ti on-bas ed su r viv al o f 128 5 p atien ts in S out hea st Nether la nds,198 4-1992. Eur J Ca ncer 200 2; 38 : 409 -13 .
  8. Culine S, Gazagne L, Yc hou M et al. Carcinoma of unknown primary. About 100 pati ents tr eated in the regional can cer ce nter of M ontpell ie r. Re v Méd lnter ne 1998; 19: 713-9.
  9. Pimiento JM, Teso D, Ma lkan A, Du dric k SJ, Palest y JA. C ancer of u nkno w n pri mary o rigi n: a d e cade o f ex pe r ience in a comm unity -b ased hospital. Am J Su rg 2007; 194: 833-8.
  10. Shaw PH, Adams R, Jordan C , Cros by TD. A Clinical R eview of th e Investigation and Mana gement of Carcino ma of Unknown Primar y in a Single Cance r Network. Clin On col 2007; 1 9: 87-95.
  11. Le Ce sne A, Le Chev al ie r T, Cail le P et al. Metastases of unkn ow n pri ma ry. Stu dy o f 3 02 auto psies. Press Méd 1 991; 20: 1369 -73 .
  12. Hainsworth JD, Greco AF. Treatment of patients with ca ncer of an unk nown primary sit e. N Engl J M ed 1993; 329: 257-63.
  13. P avlidi s N , Briasoulis E, Hainswort h J, Gr eco FA. Diagnostic and therapeutic ma nagement of canc er of an unknown prim ary. Eur J Can cer 2003; 39: 1990 -2005.
  14. Ham ilton C S, L ang la nds AO. ACUP S (ade noc arcino ma of un known primar y s ite): a c linical and cos t b enefit ana lysis. Int J Rad ia t Oncol Bio l Phys 1987; 13: 1497-503.
  15. S te wart JF, Tatt ersall M HN, Woods RL, Fox RM. Unkn ow n pri ma ry a deno carcinoma: incidence of ov er investi gation an d natu ral histor y. Br Med J 1979 ; 1: 1530 -3.
  16. Abb ruzzese JL, Abbruzzese MC , Lenzi R, H ess KR , Raber MN . Analysis of a diagnostic strateg y for patients with suspec te d tumors of unknown origin . J Clin Oncol 1995; 13: 2094-103.
  17. Bug at R, Bataill ard A, Lesimp le T et al. St and ards, Options an d Recom me ndations for the management o f patient wi th carcin oma of unknown p rimar y si te . Bu ll Cancer 200 2; 8 9: 86 9-7 5.
  18. Sporn JR, Greenb erg BR. E mpirical c he motherapy f or adenocarcinoma of u nknown pr imary tumor sit e. Sem in On col 19 93; 2 0: 26 1- 7.
  19. Greco FA, Hainsw orth JD. Ca ncer o f unkn ow n pri ma ry site. In: DeVitaV T, He llm an S, Rosenb erg S A, eds, Cancer: princi ples an d prac tice of onc ology, 8 th ed. Philadelph ia : J.B. Lipp incott Co , 20 08: 2 363-83.
  20. Pav lidis N. Fort y years e xpe rience of tr eating cance r of unkn ow n pri ma ry. Ac ta Onc ol 20 07; 3 3: 6 56-63.
  21. Culin e S, Lorthol ary A , Voigt JJ et al. A trial of the Fre nch Stud y Gro up on Carci nom as o f Un known Pri mary ( G EF CAPI 0 1).C is plat in in c om bin atio n with either gem c it ab in e or irinotecan in carcinomas of unkno wn primary site: resu lts of a randomiz ed phase II study—tr ia l for the Fre nch S tudy Gr oup o n Carcinoma s of Un known Primary (GEFCAPI0 1) . J Clin On col 20 03; 2 1: 3 479-82.
  22. Do well JE, Garr et t A M, S hyr Y, Johns on DH, Ha nde K R. A randomiz ed phase II trial in patien ts with carc inoma of a n un known pri ma ry site. Cancer 2 001; 91: 592-7.
  23. Ha in swort h JD, Spigel DR, C lark BL, et al . Pa cl itaxel/car boplati n/etoposide ver sus ge mc itabin e/ irinot eca n in t he fir st-line tre atment o f pa tients wit h carcinoma of unkn ow n pri ma ry site: a r ando mize d, p has e I II Sarah C anno n Oncolog y Researc h Co nsortiu m Tr ial. Ca ncer J 2010; 16: 70-5